Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16963368 | 1.00 | NR1H2 (0.58) | NR1H2NAMPTUSP2SMN1; SMN2MEN1 | |
| SCHEMBL16963183 | 0.88 | NR1H2 (0.52) | NR1H2HPGDGPR119JAK2JAK1 | |
| SCHEMBL16963185 | 0.88 | NR1H2 (0.52) | NR1H2HPGDGPR119JAK2JAK1 | |
| SCHEMBL1463550 | 0.85 | NR1H2 (0.59) | NR1H2NAMPTUSP2SMN1; SMN2MEN1 | |
| SCHEMBL392948 | 0.81 | USP2 (0.53) | NR1H2USP2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL18702098 | 0.81 | NR1H2 (0.58) | NR1H2NAMPTUSP2SMN1; SMN2MEN1 | |
| SCHEMBL21765673 | 0.80 | CHRNB2 (0.43) | USP2SMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL2986789 | 0.80 | NR1H2 (0.61) | NR1H2NAMPTUSP2SMN1; SMN2MEN1 | |
| SCHEMBL24693307 | 0.79 | NR1H2 (0.60) | NR1H2NAMPTUSP2SMN1; SMN2HPGD | |
| SCHEMBL17197424 | 0.79 | NR1H2 (0.60) | NR1H2NAMPTUSP2SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590940-B1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES | HOFFMANN LA ROCHE (CH) | 2021-06-09 | — | — | EP | disclosed |
| US-20200339570-A1 | BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10669268-B2 | Bicyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-02 | — | — | US | disclosed |
| EP-2900669-B1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-20180118741-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20170050960-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-23 | — | — | US | disclosed |
| US-20150353559-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2900669-A1 | NEW BICYCLIC DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669268-B2 | Bicyclic derivatives | CCNY, BICRA, UQCRB | NR1H2 1573/4885NAMPT 2194/4885USP2 4634/4885 |
| US-20170050960-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | NR1H2 1423/4885NAMPT 1861/4885USP2 4558/4885 |
| US-20180118741-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | NR1H2 1423/4885NAMPT 1861/4885USP2 4558/4885 |
| US-20150353559-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | NR1H2 1423/4885NAMPT 1861/4885USP2 4558/4885 |
| US-20200339570-A1 | BICYCLIC DERIVATIVES | CCNY, BICRA, UQCRB | NR1H2 1573/4885NAMPT 2194/4885USP2 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.